The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Are Managers Really Necessary?

In the organisational context, LEADERSHIP appears more glamorous than the word MANAGEMENT. When it comes to a team whether small or large, we need to realise that the first requirement is to be an effective manager and then a leader. Why so? First and foremost, Managers are responsible for making sure that things are done properly. And while leaders may bring us vision, inspiration and challenge, these things count for nothing without the efficient implementation brought about by good management. To be a great manager, you must have an extensive set of skills, both hard and soft – from planning and delegation to communication and motivation. The skill set is so wide, and hence, for your long-term success, it's wise to analyse your skills in all areas of management – and then to challenge yourself to improve in all of these areas. So, a fundamental question that is unasked, but lingers in the mind often is, Are managers really necessary?

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...

Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Marketing

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...

Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Policies/Sales

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...

Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Strategy

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...

Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Doctors Still Considered Noble

The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

Healthcare Disruption – Will Ola, Swiggy, Pharmaeasy, and Hospitals Converge to Deliver Health Care on Call at Your Doorstep?

How long before digital Unicorns like Ola, Swiggy, Pharmeasy, and many others realize the humongous opportunity of delivering health care at the doorstep? Imagine an app like Ola, where instead of entering where you want to go, you enter the nature of your medical need/emergency and search and find a range of hospitals/doctors/paramedics who can act as the first responders and reach your home in an ambulance or a motorbike with an HCP as a pillion rider with all necessary equipment from the thermometer to defibrillator depending on the nature of the medical care needed and triage and route you/your loved ones to the nearest hospital with an indicative cost of treatment in partnership with health insurance companies?